The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
Abstract
Advanced prostate cancer is frequently accompanied by the development of metastasis to bone. In the past, prostate cancer bone metastases were characterized as being osteoblastic (i.e., increasing bone density) based on radiographs. However, emerging evidence suggests that development of prostate cancer bone metastases requires osteoclastic activity in addition to osteoblastic activity. The complexities of how prostate tumor cells influence bone remodeling are just beginning to be elucidated. Prostate cancer cells produce a variety of pro‐osteoblastic factors that promote bone mineralization. For example, both bone morphogenetic proteins and endothelin‐1 have well recognized pro‐osteoblastic activities and are produced by prostate cancer cells. In addition to factors that enhance bone mineralization prostate cancer cells produced factors that promote osteoclast activity. Perhaps the most critical pro‐osteoclastogenic factor produced by prostate cancer cells is receptor activator of NFκB ligand (RANKL), which has been shown to be required for the development of osteoclasts. Blocking RANKL results in inhibiting prostate cancer‐induced osteoclastogenesis and inhibits development and progression of prostate tumor growth in bone. These findings suggest that targeting osteoclast activity may be of therapeutic benefit. However, it remains to be defined how prostate cancer cells synchronize the combination of osteoclastic and osteoblastic activity. We propose that as the bone microenvironment is changed by the developing cancer, this in turn influences the prostate cancer cells' balance between pro‐osteoclastic and pro‐osteoblastic activity. Accordingly, the determination of how the prostate cancer cells and bone microenvironment crosstalk are important to elucidate how prostate cancer cells modulate bone remodeling. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895
Metastases in carcinoma.Analysis of 1000 autopsied cases
Abrams, H. L., Spiro, R., & Goldstein, N. (1950) · Cancer · doi:10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7 · Cited by 1,865
Manolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenetic Protein 4
Zimmerman, L. B., De Jesús-Escobar, J. M., & Harland, R. M. (1996) · Cell · doi:10.1016/s0092-8674(00)80133-6 · Cited by 1,633
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
The Osteoblast: A Sophisticated Fibroblast under Central Surveillance
Ducy, P., Schinke, T., & Karsenty, G. (2000) · Science · doi:10.1126/science.289.5484.1501 · Cited by 1,120
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Thalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 727
Bone morphogenetic proteins in development
Hogan, B. L. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80064-5 · Cited by 705
The bone morphogenetic protein family and osteogenesis
Wozney, J. M. (1992) · Molecular Reproduction and Development · doi:10.1002/mrd.1080320212 · Cited by 681
Bone morphogenetic proteins in development
Simic, P., & Vukicevic, S. (2004) · Bone Morphogenetic Proteins: Regeneration of Bone and Beyond · doi:10.1007/978-3-0348-7857-9_4 · Cited by 672
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Metastatic prostate cancer in a transgenic mouse.
Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., & Greenberg, N. M. (1996) · PubMed · Cited by 599
Advances in Bone Biology: The Osteoclast*
ROODMAN, G. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-308 · Cited by 549
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., & Gillespie, M. T. (1999) · Endocrinology · doi:10.1210/endo.140.10.7037 · Cited by 536
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Honore, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 498
Katagiri, T., Yamaguchi, A., Ikeda, T., Yoshiki, S., Wozney, J. M., Rosen, V., Wang, E. A., Tanaka, H., Omura, S., & Suda, T. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80208-6 · Cited by 493
Bone metastases: pathophysiology and management policy.
Nielsen, O. S., Munro, A. J., & Tannock, I. F. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.509 · Cited by 486
Kingsley, D. M., Bland, A. E., Grubber, J. M., Marker, P. C., Russell, L. B., Copeland, N. G., & Jenkins, N. A. (1992) · Cell · doi:10.1016/0092-8674(92)90510-j · Cited by 482
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
The family of bone morphogenetic proteins
Ducy, P., & Karsenty, G. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00081.x · Cited by 455
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Self-citationWrana, J. L. (2000) · Cell · doi:10.1016/s0092-8674(00)81556-1 · Cited by 421
Bone morphogenetic proteins in human bone regeneration
Groeneveld, E., & Burger, E. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420009 · Cited by 404
Bone marrow, cytokines, and bone remodeling
Manolagas, S. C. (1995) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(96)82696-5 · Cited by 387
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Solloway, M. J., Dudley, A. T., Bikoff, E. K., Lyons, K. M., Hogan, B. L. M., & Robertson, E. J. (1998) · Developmental Genetics · doi:10.1002/(sici)1520-6408(1998)22:4<321::aid-dvg3>3.0.co;2-8 · Cited by 374
Carlin, B. I., & Andriole, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.0.co;2-q · Cited by 363
Yamaguchi, A., Ishizuya, T., Kintou, N., Wada, Y., Katagiri, T., Wozney, J. M., Rosen, V., & Yoshiki, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0411 · Cited by 349
Merino, R., Rodriguez-Leon, J., Macias, D., Gañan, Y., Economides, A. N., & Hurle, J. M. (1999) · Development · doi:10.1242/dev.126.23.5515 · Cited by 340
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson, J. B., Chan‐Tack, K. M., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996) · PubMed · Cited by 333
Molecular mechanisms of osteolytic bone metastases
Guise, T. A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2892::aid-cncr2>3.0.co;2-y · Cited by 331
Abe, E., Yamamoto, M., Taguchi, Y., Lecka-Czernik, B., O'Brien, C. A., Economides, A. N., Stahl, N., Jilka, R. L., & Manolagas, S. C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.663 · Cited by 319
Bone morphogenetic proteins: An unconventional approach to isolation of first mammalian morphogens
Reddi, A. H. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00049-4 · Cited by 301
Gori, F., Thomas, T., Hicok, K. C., Spelsberg, T. C., & Riggs, B. L. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1522 · Cited by 294
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 291
The mechanism of coupling: a role for the vasculature
Parfitt, A. M. (2000) · Bone · doi:10.1016/s8756-3282(00)80937-0 · Cited by 283
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. (2002) · PubMed · Cited by 270
Osteoprotegerin and RANK ligand expression in prostate cancer.
Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01122-5 · Cited by 234
Self-citationBMP7 Null Mutation in Mice: Developmental Defects in Skeleton, Kidney, and Eye
Jena, N., Martı́n-Seisdedos, C., McCue, P., & Croce, C. M. (1997) · Experimental Cell Research · doi:10.1006/excr.1996.3411 · Cited by 233
Charhon, S. A., Chapuy, M. C., Delvin, E. E., Valentin-Opran, A., Edouard, C. M., & Meunier, P. J. (1983) · Cancer · doi:10.1002/1097-0142(19830301)51:5<918::aid-cncr2820510526>3.0.co;2-j · Cited by 208
Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors
Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., & Findlay, D. M. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.640 · Cited by 197
Osteoprotegerin diminishes advanced bone cancer pain.
Luger, N. M., Honoré, P., Sabino, M., Schwei, M. J., Rogers, S. D., Mach, D. B., Clohisy, D. R., & Mantyh, P. W. (2001) · PubMed · Cited by 195
Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer
CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R. (1991) · British Journal of Urology · doi:10.1111/j.1464-410x.1991.tb15260.x · Cited by 192
Stromal factors involved in prostate carcinoma metastasis to bone
Cooper, C. R., Chay, C. H., Gendernalik, J. D., Lee, H.-L., Bhatia, J., Taichman, R. S., McCauley, L. K., Keller, E. T., & Pienta, K. J. (2003) · Cancer · doi:10.1002/cncr.11181 · Cited by 184
Self-citationKillian, C. S., Corral, D. A., Kawinski, E., & Constantine, R. I. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1506 · Cited by 178
Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro
Lin, D., Tarnowski, C. P., Zhang, J., Dai, J., Rohn, E., Patel, A. H., Morris, M. D., & Keller, E. T. (2001) · The Prostate · doi:10.1002/pros.1065 · Cited by 163
Self-citationBiochemical markers and skeletal metastases
Demers, L. M., Costa, L., & Lipton, A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z · Cited by 161
Mesoderm Induction by BMP-4 and -7 Heterodimers
Suzuki, A., Kaneko, E., Maeda, J., & Ueno, N. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6219 · Cited by 158
Schrey, M., & Patel, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.523 · Cited by 155
Kong, Y., Boyle, W. J., & Penninger, J. M. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00815.x · Cited by 153
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Ide, H., Yoshida, T., Matsumoto, N., Aoki, K., Osada, Y., Sügimura, T., & Terada, M. (1997) · PubMed · Cited by 152
Fizazi, K. S., Yang, J., Peleg, S., Sikes, C. R., Kreimann, E. L., Daliani, D., Olivé, M., Raymond, K. A., Janus, T. J., Logothetis, C. J., et al. (2003) · PubMed · Cited by 147
Guise, T. A. (1998) · Endocrine Reviews · doi:10.1210/er.19.1.18 · Cited by 146
Recent advances in bone biology provide insight into the pathogenesis of bone diseases.
Boyce, B. F., Hughes, D. E., Wright, K. R., Xing, L., & Dai, A. (1999) · PubMed · Cited by 145
Harris, S. E., Harris, M. A., Mahy, P., Feng, J. Q., Mundy, G. R., & Wozney, J. M. (1994) · The Prostate · doi:10.1002/pros.2990240406 · Cited by 144
Factors regulating the growth of metastatic cancer in bone.
Boyce, B. F., Yoneda, T., & Guise, T. A. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060333 · Cited by 143
Endothelium-derived factors as paracrine mediators of prostate cancer progression
Pirtskhalaishvili, G., & Nelson, J. B. (2000) · The Prostate · Cited by 142
Generalised Increase in Bone Resorption in Carcinoma of the Prostate
Urwin, G. H., PERCIVAL, R. C., HARRIS, S., Beneton, M. N. C., Williams, J. L., & Kanis, J. А. (1985) · British Journal of Urology · doi:10.1111/j.1464-410x.1985.tb07040.x · Cited by 140
Katagiri, T., Akiyama, S., Namiki, M., Komaki, M., Yamaguchi, A., Rosen, V., Wozney, J. M., Fujisawa‐Sehara, A., & Suda, T. (1997) · Experimental Cell Research · doi:10.1006/excr.1996.3432 · Cited by 139
Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone
Yoneda, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10132-0 · Cited by 139
Bentley, H., Hamdy, F. C., Hart, K., Seid, J. M., Williams, J. L., Johnstone, D., & Russell, R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.427 · Cited by 138
The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae
Takuwa, Y., Masaki, Τ., & Yamashita, K. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90491-5 · Cited by 129
Alam, A. S. M. T., Gallagher, A. C., Shankar, V. S., Ghatei, M. A., Datta, H. K., Huang, C. L.-H., Moonga, B. S., Chambers, T. J., Bloom, S. R., & Zaidi, M. (1992) · Endocrinology · doi:10.1210/endo.130.6.1597159 · Cited by 129
Taguchi, Y., Yamamoto, M., Yamate, T., Lin, S., Mocharla, H., DETOGNI, P., Nakayama, N., Boyce, B. F., Abe, E., & Manolagas, S. C. (1998) · PubMed · Cited by 124
Percival, R. C., Urwin, G. H., Harris, S., Yates, A. J. P., Williams, J. L., Beneton, M. N. C., & Kanis, J. A. (1987) · PubMed · Cited by 124
Autzen, P., Robson, C. N., Bjartell, A. S., Malcolm, A. J., Johnson, M. I., Neal, D. E., & Hamdy, F. C. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.658 · Cited by 123
Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., & Mundy, G. R. (2001) · PubMed · Cited by 119
Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone
Lange, P. H., & Vessella, R. L. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006106209527 · Cited by 118
Hamdy, F. C., Autzen, P., Robinson, M. C., et al. (1997) · PubMed · Cited by 117
Tsuji, K., Ito, Y., & Noda, M. (1998) · Bone · doi:10.1016/s8756-3282(97)00267-6 · Cited by 117
Vinholes, J., Coleman, R. E., & Eastell, R. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90021-3 · Cited by 117
Increased expression of bone morphogenetic protein‐7 in bone metastatic prostate cancer
Masuda, H., Fukabori, Y., Nakano, K., Takezawa, Y., cSuzuki, T., & Yamanaka, H. (2003) · The Prostate · doi:10.1002/pros.10193 · Cited by 114
Galasko, C. S. B. (1986) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198609000-00005 · Cited by 112
Brubaker, K. D., Vessella, R. L., Brown, L. G., & Corey, E. (2003) · The Prostate · doi:10.1002/pros.10233 · Cited by 107
Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105
Transcriptional Mechanisms of Bone Morphogenetic Protein-induced Osteoprotegrin Gene Expression
Wan, M., Shi, X., Feng, X., & Cao, X. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006918200 · Cited by 104
Kim, I. Y., Lee, D. H., Ahn, H. J., Tokunaga, H., Song, W., Devereaux, L., Jin, D. F., Sampath, T. K., & Morton, R. A. (2000) · PubMed · Cited by 102
Chikatsu, N., Takeuchi, Y., Tamura, Y., Fukumoto, S., Yano, K., Tsuda, E., Ogata, E., & Fujita, T. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2008 · Cited by 95
Lee, Y., Schwarz, E. M., Davies, M., Jo, M., Gates, J. J., Wu, J., Zhang, X., & Lieberman, J. R. (2002) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(02)00095-5 · Cited by 94
Correlation Between Bone Metabolic Markers and Bone Scan in Prostatic Cancer
Maeda, H. A., Koizumi, M., Yoshimura, K., Yamauchi, T., Kawai, T., & Ogata, E. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65196-6 · Cited by 90
Lee, Y.-P., Schwarz, E. M., Davies, M., Jo, M., Gates, J. J., Zhang, X., Wu, J., & Lieberman, J. R. (2002) · PubMed · Cited by 88
Osteogenic Protein-1 Stimulates Proliferation and Differentiation of Human Bone Cells in Vitro
Knutsen, R., Wergedal, J. E., Sampath, T. K., Baylink, D. J., & Mohan, S. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1973 · Cited by 86
Cornish, J., Callon, K. E., Lin, C., Xiao, C., Moseley, J. M., & Reid, I. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.6.915 · Cited by 80
Bone morphogenetic protein-6 expression in normal and malignant prostate
Barnes, J., Anthony, C. T., Wall, N. A., et al. (1995) · World Journal of Urology · doi:10.1007/bf00191214 · Cited by 69
Osteoblast Function and Osteomalacia in Metastatic Prostate Cancer
Clarke, N. W., McClure, J., & George, N. J. R. (1993) · European Urology · doi:10.1159/000474311 · Cited by 68
Bone formation and factors affecting this process
Karsenty, G. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00053-6 · Cited by 67
LI, I. W. S., Cheifetz, S., McCulloch, C. A., Sampath, K. T., & Sodek, J. (1996) · Journal of Cellular Physiology · Cited by 65
Berruti, A., Piovesan, A., TORTA, M., Raucci, C. A., Gorzegno, G., Paccotti, P., Dogliotti, L., & Angeli, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.298 · Cited by 65
RANA, A., Chisholm, G. D., KHAN, M., SEKHARJIT, S. S., Merrick, M. V., & Elton, R. A. (1993) · British Journal of Urology · doi:10.1111/j.1464-410x.1993.tb16301.x · Cited by 64
Deftos, L. J. (2000) · Cancer · Cited by 57
Molecular basis of the spectrum of skeletal complications of neoplasia
Goltzman, D., Karaplis, A. C., Kremer, R. B., & Rabbani, S. A. (2000) · Cancer · Cited by 54
Pathogenesis of Bone Metastases: Role of Tumor-Related Proteins
Rosol, T. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.844 · Cited by 51
Yorimitsu, K., Moroi, K., Inagaki, N., Saito, T., Masuda, Y., Masaki, T., & Seino, S. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1397 · Cited by 50
Retardation in Bone Resorption after Bone Marrow Ablation in Klotho Mutant Mice1
Yamashita, T., Yoshitake, H., Tsuji, K., Kawaguchi, N., Nabeshima, Y., & Noda, M. (2000) · Endocrinology · doi:10.1210/endo.141.1.7252 · Cited by 40
Endothelin‐1 localization in bone cells and vascular endothelial cells in rat bone marrow
Sasaki, T., & Hong, M.-H. (1993) · The Anatomical Record · doi:10.1002/ar.1092370306 · Cited by 37
Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells
Hullinger, T. G., Taichman, R. S., Linseman, D. A., & Somerman, M. J. (2000) · Journal of Cellular Biochemistry · Cited by 28
Calcium Studies in Ten Cases of Osteoblastic Prostatic Metastasis
Roland, S. I. (1958) · The Journal of Urology · doi:10.1016/s0022-5347(17)66278-5 · Cited by 18
Biologists abandon Popper at their peril
(2000) · doi:10.1002/(sici)1521-1878(200002)22:2
Cited by
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 393
Akech, J., Wixted, J. J., Bedard, K., van der Deen, M., Hussain, S., Guise, T. A., van Wijnen, A. J., Stein, J. L., Languino, L. R., Altieri, D. C., et al. (2010) · Oncogene · doi:10.1038/onc.2009.389 · Cited by 295
Self-citationAhn, K. S., Sethi, G., Chaturvedi, M. M., & Aggarwal, B. B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23745 · Cited by 109
Metastatic prostate cancer and the bone: significance and therapeutic options
Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.039 · Cited by 101
Metadata
- Authors
- Keller, E. T., & Brown, J.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2003-10-07
- Volume
- 91
- Issue
- 4
- Pages
- 718-729
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2149218924
- Cited by
- 298
- References
- 106
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.